Andrew J Wilson1, Kofi Sarfo-Kantanka2, Toby Barrack1, Alexandra Steck1, Jeanette Saskowski1, Marta A Crispens3, Dineo Khabele4. 1. Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Vanderbilt University Medical Center, Nashville, TN, United States. 2. Meharry Medical College, Nashville, TN, United States. 3. Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Vanderbilt University Medical Center, Nashville, TN, United States; Vanderbilt-Ingram Cancer Center, Nashville, TN, United States. 4. Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Vanderbilt University Medical Center, Nashville, TN, United States; Vanderbilt-Ingram Cancer Center, Nashville, TN, United States. Electronic address: dineo.khabele@vanderbilt.edu.
Abstract
OBJECTIVE: Homologous recombination (HR) proficient ovarian cancers, including CCNE1 (cyclin E)-amplified tumors, are resistant to poly (ADP-ribose) polymerase inhibitors (PARPi). Histone deacetylase inhibitors (HDACi) are effective in overcoming tumor resistance to DNA damaging drugs. Our goal was to determine whether panobinostat, a newly FDA-approved HDACi, can sensitize cyclin E, HR-proficient ovarian cancer cells to the PARPi olaparib. METHODS: Expression levels of CCNE1 (cyclin E), BRCA1, RAD51 and E2F1 in ovarian tumors and cell lines were extracted from The Cancer Genome Atlas (TCGA) and Broad-Novartis Cancer Cell Line Encyclopedia (CCLE). In HR-proficient ovarian cancer cell line models (OVCAR-3, OVCAR-4, SKOV-3, and UWB1.289+BRCA1 wild-type), cell growth and viability were assessed by sulforhodamine B and xenograft assays. DNA damage and repair (pH2AX and RAD51 co-localization and DRGFP reporter activity) and apoptosis (cleaved PARP and cleaved caspase-3) were assessed by immunofluorescence and Western blot assays. RESULTS: TCGA and CCLE data revealed positive correlations (Spearman) between cyclin E E2F1, and E2F1 gene targets related to DNA repair (BRCA1 and RAD51). Panobinostat downregulated cyclin E and HR repair pathway genes, and reduced HR efficiency in cyclin E-amplified OVCAR-3 cells. Further, panobinostat synergized with olaparib in reducing cell growth and viability in HR-proficient cells. Similar co-operative effects were observed in xenografts, and on pharmacodynamic markers of HR repair, DNA damage and apoptosis. CONCLUSIONS: These results provide preclinical rationale for using HDACi to reduce HR in cyclin E-overexpressing and other types of HR-proficient ovarian cancer as a means of enhancing PARPi activity.
OBJECTIVE: Homologous recombination (HR) proficient ovarian cancers, including CCNE1 (cyclin E)-amplified tumors, are resistant to poly (ADP-ribose) polymerase inhibitors (PARPi). Histone deacetylase inhibitors (HDACi) are effective in overcoming tumor resistance to DNA damaging drugs. Our goal was to determine whether panobinostat, a newly FDA-approved HDACi, can sensitize cyclin E, HR-proficient ovarian cancer cells to the PARPi olaparib. METHODS: Expression levels of CCNE1 (cyclin E), BRCA1, RAD51 and E2F1 in ovarian tumors and cell lines were extracted from The Cancer Genome Atlas (TCGA) and Broad-Novartis Cancer Cell Line Encyclopedia (CCLE). In HR-proficient ovarian cancer cell line models (OVCAR-3, OVCAR-4, SKOV-3, and UWB1.289+BRCA1 wild-type), cell growth and viability were assessed by sulforhodamine B and xenograft assays. DNA damage and repair (pH2AX and RAD51 co-localization and DRGFP reporter activity) and apoptosis (cleaved PARP and cleaved caspase-3) were assessed by immunofluorescence and Western blot assays. RESULTS: TCGA and CCLE data revealed positive correlations (Spearman) between cyclin EE2F1, and E2F1 gene targets related to DNA repair (BRCA1 and RAD51). Panobinostat downregulated cyclin E and HR repair pathway genes, and reduced HR efficiency in cyclin E-amplified OVCAR-3 cells. Further, panobinostat synergized with olaparib in reducing cell growth and viability in HR-proficient cells. Similar co-operative effects were observed in xenografts, and on pharmacodynamic markers of HR repair, DNA damage and apoptosis. CONCLUSIONS: These results provide preclinical rationale for using HDACi to reduce HR in cyclin E-overexpressing and other types of HR-proficient ovarian cancer as a means of enhancing PARPi activity.
Authors: Dariush Etemadmoghadam; George Au-Yeung; Meaghan Wall; Chris Mitchell; Maya Kansara; Elizabeth Loehrer; Crisoula Batzios; Joshy George; Sarah Ftouni; Barbara A Weir; Scott Carter; Irma Gresshoff; Linda Mileshkin; Danny Rischin; William C Hahn; Paul M Waring; Gad Getz; Carleen Cullinane; Lynda J Campbell; David D Bowtell Journal: Clin Cancer Res Date: 2013-09-04 Impact factor: 12.531
Authors: Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell Journal: J Clin Oncol Date: 2012-06-18 Impact factor: 44.544
Authors: Paul G Richardson; R Donald Harvey; Jacob P Laubach; Philippe Moreau; Sagar Lonial; Jesús F San-Miguel Journal: Expert Rev Clin Pharmacol Date: 2015-10-26 Impact factor: 5.045
Authors: Andrew J Wilson; Oluwole Fadare; Alicia Beeghly-Fadiel; Deok-Soo Son; Qi Liu; Shilin Zhao; Jeanette Saskowski; Md Jashim Uddin; Cristina Daniel; Brenda Crews; Brian D Lehmann; Jennifer A Pietenpol; Marta A Crispens; Lawrence J Marnett; Dineo Khabele Journal: Oncotarget Date: 2015-08-28
Authors: Christina E Wells; Srividya Bhaskara; Kristy R Stengel; Yue Zhao; Bianca Sirbu; Benjamin Chagot; David Cortez; Dineo Khabele; Walter J Chazin; Andrew Cooper; Vincent Jacques; James Rusche; Christine M Eischen; Laura Y McGirt; Scott W Hiebert Journal: PLoS One Date: 2013-07-22 Impact factor: 3.240
Authors: Vijayalaxmi G Gupta; Jeff Hirst; Shariska Petersen; Katherine F Roby; Meghan Kusch; Helen Zhou; Makena L Clive; Andrea Jewell; Harsh B Pathak; Andrew K Godwin; Andrew J Wilson; Marta A Crispens; Emily Cybulla; Alessandro Vindigni; Katherine C Fuh; Dineo Khabele Journal: Gynecol Oncol Date: 2021-04-16 Impact factor: 5.304
Authors: Edward Grimley; Alexander J Cole; Thong T Luong; Stacy C McGonigal; Sarah Sinno; Dongli Yang; Kara A Bernstein; Ronald J Buckanovich Journal: Theranostics Date: 2021-01-20 Impact factor: 11.556
Authors: Michelle Bilbao; Chelsea Katz; Stephanie L Kass; Devon Smith; Krystal Hunter; David Warshal; James K Aikins; Olga Ostrovsky Journal: Biomolecules Date: 2021-11-17